文献速递乳腺癌

早期ERBB2/HER2阳性乳腺癌中免疫相关基因表达特征与肿瘤浸润淋巴细胞的预后和预测价值:CALGB 40601与PAMELA试验的相关性分析

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
PubMed 文献 · JAMA Oncol · 2023-01-01

该研究对CALGB 40601和PAMELA两项试验的预处理肿瘤样本进行RNA测序免疫相关基因表达谱和TILs评估,分析其与pCR和EFS的关联。结果显示TILs与pCR显著相关,36个免疫特征与更高pCR率显著相关,其中7个优于TILs(6个为B细胞相关);校正临床病理因素后,免疫球蛋白G特征而非TILs与EFS独立相关。作者认为多种B细胞相关特征比主要代表T细胞的TILs与pCR和EFS关联更强,当两者均可获得时免疫相关特征的预后价值似乎更优。

要点

  • 在两项试验合并分析中,TILs与pCR显著相关(OR 1.01,95%CI 1.01-1.02,P=.02)。
  • 36个免疫特征与更高pCR率显著相关,其中7个预测pCR优于TILs,6个为B细胞相关。
  • 校正临床病理因素后,免疫球蛋白G特征与EFS独立相关(校正HR 0.63,95%CI 0.42-0.93,P=.02),TILs无独立关联(校正HR 1.00,95%CI 0.98-1.02,P=.99)。

核心结论

  • 作者认为多种B细胞相关特征比主要代表T细胞的TILs与pCR和EFS关联更强,当TILs和基因表达均可获得时免疫相关特征的预后价值似乎更优。

研究设计与样本

  • 该研究为CALGB 40601和PAMELA两项临床试验的相关性预后分析。
  • CALGB 40601试验中305例患者随机接受每周紫杉醇联合曲妥珠单抗、拉帕替尼或两者联合治疗16周,主要终点为pCR,次要终点为EFS。
  • PAMELA试验中151例患者接受曲妥珠单抗联合拉帕替尼新辅助治疗18周,主要终点为HER2富集亚型预测pCR的能力。
  • CALGB 40601试验于2008年12月至2012年2月开展,PAMELA试验于2013年10月至2015年11月开展,数据分析于2020年6月1日至2022年1月1日进行。
  • 对CALGB 40601试验230例和PAMELA试验138例预处理肿瘤进行RNA测序免疫相关基因表达谱和TILs评估,采用逻辑回归和Cox分析研究生物标志物与pCR(两试验)及EFS(CALGB 40601)的关联。

主要发现

  • 患者中位年龄50岁(IQR 42-50岁),305例(100%)为女性。
  • 202个免疫特征中166个(82.2%)与TILs显著相关。
  • 两试验合并分析中,TILs与pCR显著相关(OR 1.01,95%CI 1.01-1.02,P=.02)。
  • 除TILs外,36个免疫特征与更高pCR率显著相关,其中7个预测pCR优于TILs,6个为B细胞相关。
  • 在校正包括PAM50内在肿瘤亚型在内的临床病理因素的多变量Cox模型中,免疫球蛋白G特征与EFS独立相关(校正HR 0.63,95%CI 0.42-0.93,P=.02),TILs无独立关联(校正HR 1.00,95%CI 0.98-1.02,P=.99)。

关键数值与推荐

  • TILs与pCR的关联:OR 1.01(95%CI 1.01-1.02,P=.02),基于两试验合并分析。
  • 免疫球蛋白G特征与EFS的关联:校正HR 0.63(95%CI 0.42-0.93,P=.02),基于CALGB 40601试验多变量Cox模型。
  • TILs与EFS的关联:校正HR 1.00(95%CI 0.98-1.02,P=.99),基于CALGB 40601试验多变量Cox模型。
  • 202个免疫特征中166个(82.2%)与TILs显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Both tumor-infiltrating lymphocytes (TILs) assessment and immune-related gene expression signatures by RNA profiling predict higher pathologic complete response (pCR) and improved event-free survival (EFS) in patients with early-stage ERBB2/HER2-positive breast cancer. However, whether these 2 measures of immune activation provide similar or additive prognostic value is not known. OBJECTIVE: To examine the prognostic ability of TILs and immune-related gene expression signatures, alone and in combination, to predict pCR and EFS in patients with early-stage ERBB2/HER2-positive breast cancer treated in 2 clinical trials. DESIGN, SETTING, AND PARTICIPANTS: In this prognostic study, a correlative analysis was performed on the Cancer and Leukemia Group B (CALGB) 40601 trial and the PAMELA trial. In the CALGB 40601 trial, 305 patients were randomly assigned to weekly paclitaxel with trastuzumab, lapatinib, or both for 16 weeks. The primary end point was pCR, with a secondary end point of EFS. In the PAMELA trial, 151 patients received neoadjuvant treatment with trastuzumab and lapatinib for 18 weeks. The primary end point was the ability of the HER2-enriched subtype to predict pCR. The studies were conducted from October 2013 to November 2015 (PAMELA) and from December 2008 to February 2012 (CALGB 40601). Data analyses were performed from June 1, 2020, to January 1, 2022. MAIN OUTCOMES AND MEASURES: Immune-related gene expression profiling by RNA sequencing and TILs were assessed on 230 CALGB 40601 trial pretreatment tumors and 138 PAMELA trial pretreatment tumors. The association of these biomarkers with pCR (CALGB 40601 and PAMELA) and EFS (CALGB 40601) was studied by logistic regression and Cox analyses. RESULTS: The median age of the patients was 50 years (IQR, 42-50 years), and 305 (100%) were women. Of 202 immune signatures tested, 166 (82.2%) were significantly correlated with TILs. In both trials combined, TILs were significantly associated with pCR (odds ratio, 1.01; 95% CI, 1.01-1.02; P = .02). In addition to TILs, 36 immune signatures were significantly associated with higher pCR rates. Seven of these signatures outperformed TILs for predicting pCR, 6 of which were B-cell related. In a multivariable Cox model adjusted for clinicopathologic factors, including PAM50 intrinsic tumor subtype, the immunoglobulin G signature, but not TILs, was independently associated with EFS (immunoglobulin G signature-adjusted hazard ratio, 0.63; 95% CI, 0.42-0.93; P = .02; TIL-adjusted hazard ratio, 1.00; 95% CI, 0.98-1.02; P = .99). CONCLUSIONS AND RELEVANCE: Results of this study suggest that multiple B-cell-related signatures were more strongly associated with pCR and EFS than TILs, which largely represent T cells. When both TILs and gene expression are available, the prognostic value of immune-related signatures appears to be superior.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fernandez-Martinez A, Pascual T, Singh B, et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023. PMID: 36602784. doi:10.1001/jamaoncol.2022.6288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。